Radium-223, enzalutamide, and a bone-protecting agent may be a new treatment option for mCRPC patients with bone metastases, according to Silke Gillessen, MD.

Truqap combination showed a statistically and clinically meaningful improvement in radiographic progression-free survival for ...

The company will evaluate the Hepzato kit as a combination therapy with the standard of care in patients with liver-dominant ...

Elacestrant, a selective estrogen receptor degrader, demonstrated significant improvements in progression-free survival (PFS) ...

Androgen deprivation is the mainstay of advanced prostate cancer treatment. Despite initial responses, almost all patients progress to castration-resistant prostate cancer (CRPC). The ...

The dual primary end points, assessed in patients with centrally confirmed MSI-H or dMMR unresectable or metastatic colorectal cancer, were progression-free survival as determined by blinded ...

However, the author's preference is to offer use of cabazitaxel as the next step for patients with good performance status, symptomatic progression ... for metastatic prostate cancer, so once ...

STAG2 loss in Ewing sarcoma alters enhancer-promoter contacts dependent and independent of EWS::FLI1- ...

Delcath Systems, Inc. , an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced that the U.S. Food and Drug Administration (FDA) has ...

Oct. 9, 2024 — Researchers have demonstrated that patients with metastatic non-squamous non-small cell lung cancer (NSCLC) harboring specific mutations in the STK11 ... Scientists Discover That ...

Cervical Cancer Deaths in Young Women Plummet After Introduction of HPV Vaccine Nov. 27, 2024 — Researchers found a reduction in cervical cancer mortality in women under the age of 25 ...